Literature DB >> 12021938

Stroke prevention: management of modifiable vascular risk factors.

Didier Leys1, Dominique Deplanque, Claire Mounier-Vehier, Marie-Anne Mackowiak-Cordoliani, Christian Lucas, Régis Bordet.   

Abstract

Stroke prevention is a crucial issue because (i) stroke is a frequent and severe disorder, and (ii) acute stroke therapies that are effective at the individual level have only a little impact in term of public health. Stroke prevention consists of the combination of 3 strategies: an optimal management of vascular risk factors, associated when appropriate with antithrombotic therapies, carotid surgery, or both. Primary prevention trials have shown that reducing blood pressure in hypertensive subjects reduces their vascular risk, including stroke. The association of perindopril plus indapamide reduces the vascular risk in patients who have had a stroke or TIA during the last 5 years, irrespective of their baseline blood pressure. Lowering serum cholesterol with statins or gemfibrozil in patients with hypercholesterolemia or coronary heart disease (CHD), reduces the risk of stroke. However, no trial of cholesterol-lowering therapy has been completed in stroke patients. A strict control of high cholesterol levels should be encouraged, because of benefits in terms of CHD. Statins should be prescribed for stroke patients with CHD, or increased cholesterol levels. Cigarette smoking is associated with an increased risk of stroke and should be avoided. Careful control of all risk factors, especially arterial hypertension in type 1 and type 2 diabetics is recommended, together with a strict glycemic control to reduce systemic microvascular complications. Estrogens prescribed in hormone replacement or oral contraceptive therapies are not recommended after an ischemic stroke. It is also recommended to reduce alcohol consumption and obesity, and to increase physical activity in patients at risk for first-ever or recurrent stroke. An optimal management of risk factors for stroke is crucial to reduce the risks of first-ever stroke, recurrent stroke, any vascular event after stroke and vascular death. One of the major public health issues for the coming years will be to focus more on risk factor recognition and management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021938     DOI: 10.1007/s004150200057

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes.

Authors:  Weiguo Li; Aisha I Kelly-Cobbs; Erin M Mezzetti; Susan C Fagan; Adviye Ergul
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

2.  The quality of diabetes care following hospitalization for ischemic stroke.

Authors:  Nancy Pandhi; Maureen A Smith; Amy J H Kind; Jennifer R Frytak; Michael D Finch
Journal:  Cerebrovasc Dis       Date:  2009-01-29       Impact factor: 2.762

3.  Major depressive disorder and stroke risks: a 9-year follow-up population-based, matched cohort study.

Authors:  Cheng-Ta Li; Ya-Mei Bai; Pei-Chi Tu; Ying-Chiao Lee; Yu-Lin Huang; Tzeng-Ji Chen; Wen-Han Chang; Tung-Ping Su
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

4.  Secondary prevention after ischemic stroke. Evolution over time in practice.

Authors:  Marie Girot; Marie-Anne Mackowiak-Cordoliani; Dominique Deplanque; Hilde Hénon; Christian Lucas; Didier Leys
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

5.  Endothelium-dependent impairments to cerebral vascular reactivity with type 2 diabetes mellitus in the Goto-Kakizaki rat.

Authors:  Brayden D Halvorson; Shawn N Whitehead; John J McGuire; Robert W Wiseman; Jefferson C Frisbee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-05-15       Impact factor: 3.619

Review 6.  Sex differences in stroke.

Authors:  Roy A M Haast; Deborah R Gustafson; Amanda J Kiliaan
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-03       Impact factor: 6.200

7.  Risk reduction strategies in ischaemic stroke : the role of antiplatelet therapy.

Authors:  Mark J Alberts; Richard Atkinson
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC Potsdam Study.

Authors:  Cornelia Weikert; Klaus Berger; Christin Heidemann; Manuela M Bergmann; Kurt Hoffmann; Kerstin Klipstein-Grobusch; Heiner Boeing
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 9.  Stroke in patients with diabetes and hypertension.

Authors:  Samy I McFarlane; Domenic A Sica; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-05       Impact factor: 3.738

10.  Transient ischaemic attacks are associated with increased rates of global cerebral atrophy.

Authors:  R J L Walters; N C Fox; J M Schott; W R Crum; J M Stevens; M N Rossor; D J Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.